|

combination of Trilaciclib and Pemetrexed Clinical Trials

1 actively recruiting trial

Also known as: CDK 4/6 inhibitor, G1T28

Pipeline

Phase 2: 1

Top Sponsors

  • Jiangsu Province Nanjing Brain Hospital1

Indications

  • NSCLC1
  • Lung Cancer1
  • Cancer1

Other1 trial

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.